Was your credit card unexpectedly rejected? Or have you spotted unfamiliar charges on your bank statement? These are just a couple signs of potential identity theft. (Source: Federal Trade Commission)

Once you realize your identity has been compromised, you need to act fast. But don’t panic; this guide will walk you through each step you need to take to be sure you recover as quickly as possible.

The gene therapy company has made three distinct moves over the past week that reinforce its intention to get products to market after a decade in business.

GlaxoSmithKline and Pfizer have finally closed on a multibillion-dollar merger that combined their consumer healthcare businesses, creating the world’s largest over-the-counter business.

The pharmaceutical giants — which own household names like Advil and Tums — announced the joint venture back in December 2018.

A venture capital firm formed by a founder of one of the first companies to win Food and Drug Administration approval for a cell therapy for cancer closed a new fund worth more than half of $1 billion.

Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale. 

What’s it like having two high-profile jobs at once? Ask Brian Darmody, who’s been serving the University of Maryland College Park (UMCP) since 1982 and long ago ascended to the position of associate vice president. Darmody recently accepted a new position as CEO with the Association of University Research Park (AURP), which will keep him in the local focus as he works toward retiring from UMCP at the end of 2019 – while continuing to work out of the Discovery District at UMCP and pursue new challenges.

Magenta Medical, the heart failure solutions developer based on proprietary miniaturized blood pump technology announced they have raised funds Monday in a round led by global venture capital firm New Enterprise Associates (NEA.)

You might have lost count of how many times Roche has extended the tender offer period for shares of Spark Therapeutics. As of Wednesday, it's five. And once again, regulatory delays are part of the problem.

Montgomery County Economic Development Corporation - Maryland is excited to be attending Site Selectors Guild Fall Forum this September 9-11th in Dallas! We're looking forward to connecting with Guild members to tell them about all the great business assets Montgomery County has to offer! hashtag#SSG hashtag#econdev hashtag#siteselection hashtag#Dallas

The University System of Maryland (USM) has named Claire Broido Johnson, MBA, as Managing Director of the Maryland Momentum Fund (MMF), a $10 million investment fund that supports early-stage companies affiliated with USM institutions. She joins the USM this week.

Anne Lindblad, PhD, joined Emmes in 1982 as a Biostatistician and currently serves as the President and CEO of the company. She has supported clinical research throughout her career, serving as Principal Investigator of projects spanning diverse disease areas, including neurology, ophthalmology, oncology, dialysis, transplantation, speech and hearing, and dentistry.

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for delivery into the Strategic National Stockpile (SNS) over 12 months. This contract option was exercised under the company’s 2016 development and procurement contract with BARDA, valued at up to $1.5 billion, that includes a five-year base period of performance to develop AV7909 for post-exposure prophylaxis of anthrax disease and to deliver an initial three million doses to the SNS, as well as contract options for procurement of up to an additional 50 million doses. This exercise of the contract option through a modification is the first such option for procurement of doses to follow the initial deliveries of doses under the base contract.

The Johns Hopkins Hospital is once again ranked #3 in the nation out of more than 4,600 hospitals reviewed for U.S. News & World Report’s 2019–20 Best Hospitals list, which was released today.

Mayo Clinic and medical device giant Boston Scientific are slated to announce a new med-tech accelerator Monday. 

The collaboration will be located in One Discovery Square, a new building in Rochester adjacent to Mayo Clinic that's meant to attract medical technology startups.

The U.S. Economic Development Administration awarded more than $600,000 to a division of Johns Hopkins University on Tuesday to increase economic development in the region’s digital health field.

gel-e is developing a line of advanced hemostatic and wound treatment products that address unmet needs from the operating room to the backyard.  Following previous clearances for topical and external use of its platform technology (see http://www.gel-e.co/news.html), the Company is now expanding its label to include use for internal and surgical applications.  The first product, now on an accelerated path as a Breakthrough Device, is an expanding injectable hemostat, Life Foam™.   Life Foam can rapidly provide temporary control of bleeding from non-compressible abdominal wounds that are not amenable to tourniquet application in trauma and battlefield conditions.  As the tradename suggests, this product is designed to save the lives of those injured in battle, or that are the victims of traumatic accidents or even terrorist attacks.  

In the last five to 10 years, it would seem as though Baltimore is finally emerging (at least economically) — from its slow, multi-decade decline. But if you’re a resident of one of the city’s poorer neighborhoods, you might not know it.

A nice, relaxing glass of Bordeaux or Cabernet might easily seem like the perfect treatment for an anxious or slightly depressed state. Though, the alcohol might lead one down a slippery path rather quickly. Instead, investigators at the University of Buffalo (UB) and Xuzhou Medical University in China have decided to focus their attention on the widely studied plant compound—found in considerably higher levels in red wine than most other plants—called resveratrol. This phenolic compound has been studied for several decades, in connection with reduced incidence of cardiovascular disease and for the treatment of cancer, with mixed results. Yet now, researchers found new evidence of resveratrol displaying anti-stress effects by blocking the expression of an enzyme related to the control of stress in the brain.

A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of  oncology and central nervous system disorders.

Venn Innovation, a non-profit Moncton-based incubator established to connect New Brunswick’s tech ecosystem, has received approximately $475,000 from the federal government in the form of a grant.

BrainScope announced today that it has successfully completed a nearly five year, $9.9 million U.S. Department of Defense research contract supporting the development and validation of an objective marker of the presence and severity of concussion. In a large blinded validation study, the system demonstrated its ability to help clinicians assess concussion at the time of injury, reflect severity of injury, and aid in their assessment of readiness to return to activity. BrainScope extended the work performed under this Department of Defense contract to include adolescents funded through private investment from BrainScope and a second award from the NFL-GE Head Health Challenge I.

The Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System announces its 7th Annual Pediatric Device Innovation Symposium is slated for Sunday, Sept. 22 in Boston, Mass., featuring a $150K medical device competition focused on innovations for neonatal and NICU care. Following the theme "Pediatric Device Clinical Trials: Forging a Better Path," this year's symposium explores the pediatric device clinical trial process, including progress insights, current challenges and potential solutions.

Venture capital fundraising this year by biopharma startups is on course to fall behind last year, though it will be above the figure for 2017. But the biggest story may be where that funding is going.

Frederick, Maryland continues to be a hotbed for biotech and a destination of choice for many new startups. The last few years have seen one-time startups like RoosterBio, Inc., BioFactura, Inc. and Akonni Biosystems thrive and grow within the Frederick life science support ecosystem. 

A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders.

If you attended any of the events, conferences and panel discussions in the BioHealth Capital Region this year you probably would have picked up on a consistent theme. Whether it was at the ISPE Chesapeake Bay Area Chapter’s MAST Showcase, the BioHealth Capital Region Forum held at AstraZeneca in April or the more recent NCI Tech Transfer Showcase, talent and capital were hot button topics discussed intensely during the sessions, over lunch and while networking at each event. 

Emmes today announced that it has received a Workplace Excellence Seal of Approval from Alliance for Workplace Excellence (AWE). This is the fifth consecutive year the company has received the AWE Workplace Excellence award.

AUTM - #Egypt tech transfer partnership and information exchange co-sponsored by the USDA continues this week with stops this week at #Maryland TEDCO and BioHealth Innovation, Inc. in the BioHealth Capital Region

Scientists are getting closer to understanding how to turn the body’s energy-storing white fat cells into energy-burning beige fat cells, opening up hopes that fat deposits could one day be deliberately manipulated to prevent obesity and related health conditions.

MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has appointed Dr. Dhana Chinnasamy, a 20+-year expert in the research and translation of gene and immunotherapies, as its Vice President, Non-Clinical and Translational Studies. In her new role, Dr. Chinnasamy will oversee all non-clinical and translational activities for MaxCyte's CARMA platform working closely with the clinical, regulatory, manufacturing, and business development teams in support of MaxCyte's clinical-stage therapeutic development.

The Biotechnology Innovation Organization (BIO) recently released the report Transforming Ideas into Advances: Best Practices in State and Regional Bioscience Economic Development Initiatives. This biennial report provides a good summary of state initiatives serving the industry plus a discussion of new developments by state.

The 24-week, part-time program will be geared toward working professionals, who may be looking to pursue new job opportunities in tech.

I recently visited Egypt as part of a team led by the Departments of State and Agriculture, supported by the good folks at the AUTM Foundation. Egypt, like many countries, is looking at our model for integrating research universities into their economy. I was asked to speak about the Bayh-Dole Act and thought it was important to emphasize that there were many factors required beyond enacting a law to reverse an entrenched national policy.

Elon Musk grabbed a lot of attention with his July 16 announcement that his company Neuralink plans to implant electrodes into the brains of people with paralysis by next year. Their first goal is to create assistive technology to help people who can’t move or are unable to communicate.

Venture capital fundraising this year by biopharma startups is on course to fall behind last year, though it will be above the figure for 2017. But the biggest story may be where that funding is going.